Unbiased Analysis of Today's Healthcare Issues
Costs and benefits of advance preparations for future pandemics. ISPOR Europe Round-ups: Day 1, 2 and 3 Impending intergenerational crisis. Limited COVID-19 vaccine externalities? Free insulin (not real) Puerto Rico’s health success in the mid-20th century.
That was the title of the second plenary at ISPOR Europe this year. One interesting slide from Nancy Devlin who outlined how different countries used different patient-reported outcome measures (PROMs). English NHS PROMs programme. Variation in provider performance linked to reimbursement UK Private Healthcare Information Network (PHIN). Part of an initiative to improve patient choice…
That is the quote from Iga Lipska, MD, PhD, MPH from the Medical University of Gdańsk, Clinical Trials Center in Warsaw, Poland. She was one the panelists at the ISPOR Europe Plenary speech. There were a lot of good sessions, many of which I will be posting on throughout the week. The first plenary was…
I am happy to announce that along with co-authors Alen Marijam, Ashish V. Joshi, Fanny S. Mitrani-Gold, Katie Everson, Rifat Tuly, Peter Rosenquist, Michael Gillam & Maria Elena Ruiz, I have a new paper published in Antimicrobial Resistance & Infection Control titled “Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among…
Many people believe that the US is a fee-for-service system and many European countries are more likely to use global capitation reimbursement for providers. Those who dislike fee-for-service claim it incentivize over-treatment and disincentives prevention and use terms like “waste” and “too expensive”. Those who dislike global capitation claim that approach leads to reduced access…
Are you at risk of your physician dropping you? Rankings offer no sense of scale. Cardiac xenotransplantation. What is a square? Neighborhood Atlas.
As part of The 21st Century Cures Act, FDA is required to consider additional mechanisms to expedite access to new drugs, including those currently under investigation. In fact, the 21st Century Cure Act mandates that pharmaceutical manufacturers have to post their policies on expanded access (a.k.a. “compassionate use”) for investigational drugs by: (1) the first…
Antibiotic resistance is an increasing problem. My own research shows that when infections are antibiotic resistance, the risk of complications rises as does the cost to treat the infection. According to the CDC, antimicrobial resistance is a major public health problem: …killing at least 1.27 million people worldwide and associated with nearly 5 million deaths…